Overview
BPC-157 and TB-500 are the two most commonly discussed peptides in the tissue repair and recovery research space. Both have been studied primarily in animal models, and both target overlapping — but distinct — biological pathways.
This comparison breaks down what the research actually shows about each compound, where they overlap, where they differ, and what the evidence says about combining them.
Quick Comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound-157 | Thymosin Beta-4 fragment |
| Molecular Weight | 1,419.5 g/mol | 889.0 g/mol |
| Origin | Gastric juice protein | Thymus gland protein |
| Primary Research Focus | GI protection, tendon/tissue repair | Wound healing, cardiac repair |
| Research Status | Animal models (100+ studies) | Animal models (60+ studies) |
| Half-Life | ~4 hours | ~2-3 hours |
| CAS Number | 137525-51-0 | 77591-33-4 |
| Human Trial Data | None published | Limited (wound healing) |
Mechanism Differences
BPC-157 appears to work primarily through:
- VEGF-mediated angiogenesis (new blood vessel growth)
- Nitric oxide system modulation
- Growth factor expression (EGF, FGF)
- Interaction with the dopaminergic system
TB-500 appears to work primarily through:
- Actin sequestration and cell migration
- Anti-inflammatory cytokine modulation
- Blood vessel growth via different pathways than BPC-157
- Regulation of cell building proteins
The key difference: BPC-157 research emphasizes vascular and GI pathways, while TB-500 research emphasizes cellular migration and inflammatory modulation. These are complementary rather than redundant mechanisms.
Research Evidence by Application
Tendon and Ligament Repair
- BPC-157: Multiple rat studies showing accelerated Achilles tendon healing, improved collagen organization
- TB-500: Fewer studies on tendons specifically, but positive results in dermal wound models that share similar repair mechanisms
- Edge: BPC-157 has more tendon-specific research
Muscle Recovery
- BPC-157: Studies in rat muscle crush injury showing functional recovery improvements
- TB-500: Studies showing improved muscle regeneration markers, particularly after ischemic damage
- Edge: Roughly comparable evidence base
Gut Health
- BPC-157: Extensive GI research — multiple ulcer models, colitis models, GI motility studies
- TB-500: Minimal GI-specific research
- Edge: BPC-157 clearly stronger for gut applications
Cardiac/Cardiovascular
- BPC-157: Some research on blood pressure modulation and vascular effects
- TB-500: Stronger cardiovascular research — studied for post-MI cardiac repair in animal models
- Edge: TB-500 has more cardiovascular-specific data
The Blend Approach
Several research suppliers offer BPC-157 + TB-500 combination products. The rationale is mechanistic complementarity:
- BPC-157 drives vascularization and GI protection
- TB-500 drives cell migration and anti-inflammatory effects
- Together, they may address tissue repair from two angles simultaneously
Evidence for the combination: There are very few studies examining both compounds together. The synergy hypothesis is based on their non-overlapping mechanisms, not on direct combination studies. This is an important distinction.
Honest Assessment
Both compounds are promising in animal research, but neither has robust human clinical data. The peptide research community's enthusiasm often outpaces the actual evidence base. Key caveats:
- Animal models don't always translate to human outcomes
- Optimal dosing in humans is unknown for both compounds
- Long-term safety profiles are not established
- Most studies come from a small number of research groups
For research purposes only. Not medical advice.
Want a personalized protocol?
Take the assessment and we'll match you to the right research stack based on your goals.
Start your assessment →